Gelteq Limited Ordinary Shares (GELS) Stock Score, Valuation & Financial Research

Gelteq Limited Ordinary Shares is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for GELS

Gelteq Limited Ordinary Shares does not currently have a complete Wall Street Score. The stored market price is USD 0.52. These figures are a research snapshot, not a buy or sell recommendation.

What Gelteq Limited Ordinary Shares does

Gelteq Limited, established in 2017 and based in Caulfield, Australia, specializes in creating and commercializing advanced gel-based delivery methods for both human and animal use. The company offers customizable, white-label gel formulations that can be applied to a broad array of goods, such as prescribed pharmaceuticals, non-prescription remedies, nutritional supplements (including sports-related products), and veterinary care items.

Company business and revenue

Research reporting period: 2025-06-30. A research update is not a new financial filing.

How the company makes money

Gelteq operates as a clinical and science-based company that develops and commercializes white-label gel-based delivery solutions. The company generates revenue by producing these proprietary gel-based dosage forms for other companies, which then rebrand and sell the products as their own within the pharmaceutical, nutraceutical, pet care, and sports sectors.

Products and services

  • Proprietary edible gel-based oral drug delivery systems and dosage forms applied across five core verticals: pets, sports, pharmaceutical, over-the-counter (OTC), and nutraceuticals.

Customer types

Pharmaceutical companies; Nutraceutical companies; Pet care and veterinary companies; Sports performance brands.

Disclosed major customers

  • Shenzhen Mana Health Management Co. Source

Suppliers, materials and equipment

  • Contract manufacturing and raw material suppliers — The company relies on third-party suppliers for raw materials and contract manufacturing services; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Hong Kong Flag Football Program — A commercial partnership announced in December 2025 to further Gelteq's presence in Asia. Source

Business strengths to evaluate

  • Proprietary patent-pending gel-based delivery technology Source

Business risks and research considerations

  • History of operating losses and dependence on external financing Source
  • Reliance on third-party manufacturing and supply chain partners Source

Sources: Company research source · Shenzhen Mana Health Management Co.

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

GELS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.52
Market capitalization:
4.79M (currency not supplied)
Revenue:
USD 124.23K
Net income:
USD -3.9M
Free cash flow:
USD -4.29M
Cash:
USD 6.5K
Total debt:
USD 3.56M
EPS:
USD -0.42

What stands out

  • Reported year-over-year revenue growth is +7.8%.
  • Free cash flow is USD -4.29M, negative for the stored period.
  • The balance sheet shows USD 6.5K of cash versus USD 3.56M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -3451.4% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -3137.1% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Debt exceeds cash by USD 3.55M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for GELS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • Can GELS maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
  • How long can GELS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is GELS's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What specifically needs to improve for GELS to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of GELS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research GELS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.